Abstract
A stability-indicating reversed-phase liquid chromatographic method for the determination of atenolol was developed. Different chromatographic conditions were carefully studied to optimize the parameters for the evaluation of the studied drug. The chromatographic assay involved the use of a C8 Column (250 mm×4.6 mm i.d., 5 μm) with a simple mobile phase composed of acetonitrile:methanol:0.02 M phosphate buffer, pH 5 (20:20:60) at a flow rate of 1 ml/min and UV detection at 226 nm. Pindolol was used as an internal standard. The method showed good linearity over the range of 0.05-10 μg/mL with a detection limit of 0.01 μg/mL and a quantitation limit of 0.03 μg/mL. The proposed method was successfully applied for the analysis of atenolol in three commercial tablets with average percent recoveries of 100.14 ± 1.04, 100.20 ± 0.92, 100.00 ± 0.91 and 100.75 ± 0.67, respectively. Several co-formulated and co-administered drugs did not interfere with the proposed method. The results were statistically compared with those obtained by the official method and were found to be in good agreement. The stability-indicating capability of the method was also tested after accelerated degradation of atenolol in acidic and basic media and after freezing and heating treatments.
Highlights
Atenolol, (2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy] phenyl]acetamide [1] (Figure 1), is a cardioselective beta blocker and reported to lack intrinsic sympathomimetic activity and membranestabilizing properties
Degradation products did not interfere with the intact atenolol peak as shown in figures 7 and 8. These results demonstrated the ability of the proposed method to be used as a stability-indicating HPLC method for the analysis of atenolol
The proposed method for the determination of atenolol based on the use of liquid chromatography with spectrophotometric detection was shown to be reliable, simple, accurate, sensitive and precise
Summary
Atenolol, (2-[4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino]propoxy] phenyl]acetamide [1] (Figure 1), is a cardioselective beta blocker and reported to lack intrinsic sympathomimetic activity and membranestabilizing properties. It is used in the management of hypertension, angina pectoris, cardiac arrhythmias, and myocardial infarction. Different analytical methods were developed for the determination of atenolol. In the present work an accurate, sensitive and selective reversed-phase liquid chromatographic method for the determination of atenolol in presence of some co-formulated or co-administered drugs was developed. The mobile phase was acetonitrile:methanol:0.02 M phosphate buffer, pH 5 [20:20:60]. This solution was stable for at least 7 days when kept in the refrigerator
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
